Acta Scientific Nutritional Health (ASNH)(ISSN: 2582-1423)

Short Communication Volume 4 Issue 5

Things to be Know about the Coronavirus Illness (The Era of Covid-19)

Vinayaka AM*

Department of Periodontics and Implantology, Karnataka, India

*Corresponding Author: Vinayaka AM, Department of Periodontics and Implantology, Karnataka, India.

Received: March 20, 2020; Published: April 09, 2020

×

  Coronavirus illness 2019 (COVID-19) is an infectious disease caused by the virus strain "severe acute metabolic process syndrome coronavirus 2" (SARS-CoV-2). The illness was 1st known in 2019 in Wuhan, China, and has since unfold globally, leading to the 2019-20 coronavirus pandemic. Common symptoms include fever, cough and shortness of breath. Muscle pain, sputum production and raw throat area unit less common. While the bulk of cases end in gentle symptoms, some attain severe pneumonia and multi-organ failure. As of twenty March 2020, the rate of deaths per range of diagnosed cases is four. 1%, however ranges from zero.2% to fifteen betting on age and different health issues [1,2].

×

References

  1. National Health Commission (2020).
  2. Diao Y., et al. "Estimating the cure rate and case fatality rate of the ongoing epidemic COVID-19". Med Rxiv (2020).
  3. “2019-nCoV: preliminary estimates of the confirmed-case-fatality-ratio and infection-fatality-ratio, and initial pandemic risk assessment". institutefordiseasemodeling.github.io (2020).
  4. "Report 4: Severity of 2019-novel coronavirus (nCoV)" (2020).
  5. Chen H., et al. "Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records". Lancet 395 (2020): 809-815.
  6. Cui P., et al. "Clinical features and sexual transmission potential of SARS-CoV-2 infected female patients: a descriptive study in Wuhan, China". Med Rxiv (2020).
  7. "Total confirmed cases of COVID-19 per million people". Our World in Data (2020).
  8. "Total confirmed deaths due to COVID-19 per million people". Our World in Data (2020).
  9. "Novel coronavirus named 'Covid-19': WHO". TODAY online (2020).
  10. "The coronavirus spreads racism against – and among – ethnic Chinese". The Economist (2020).
  11. "Naming the coronavirus disease (COVID-19) and the virus that causes it". World Health Organization (WHO) (2020).
  12. "Novel Coronavirus(2019-nCoV) Situation Report-10". World Health Organization (WHO) 30 (2020).
  13. Cascella M., et al. "Features, Evaluation and Treatment Coronavirus (COVID-19)". Stat Pearls (2020).
  14. Chen WH., et al. "The SARS-CoV-2 Vaccine Pipeline: an Overview". Current Tropical Medicine Reports (2020).
  15. Roberts M. "Coronavirus: US volunteers test first vaccine". BBC News (2020).
  16. Ko WC., et al. "Arguments in favor of remdesivir for treating SARS-CoV-2 infections". International Journal of Antimicrobial Agents (2020): 105933.
  17. Wang M., et al. "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) In vitro". Cell Research3 (2020): 269-271.
  18. Beeching NJ., et al. "BMJ Best Practices: COVID-19". BMJ (2020).
  19. "AIFA e Gilead annunciano che l'Italia è tra i Paesi che testeranno l'antivirale remdesivir per il trattamento del COVID-19". aifa.gov.it (2020).
  20. Gao J., et al. "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies". Bioscience Trends1 (2020): 72-73.
  21. Yao X., et al. "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)". Clinical Infectious Diseases (2020).
  22. Touret F and de Lamballerie X. "Of chloroquine and COVID-19". Antiviral Research 177 (2020): 104762.
  23. Multicenter collaboration group of Department of Science Technology of Guangdong Province Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia (February 2020). "[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]". Zhonghua Jie He He Hu Xi Za 3 (2020): 185-188.
  24. "Azioni intraprese per favorire la ricerca e l'accesso ai nuovi farmaci per il trattamento del COVID-19". (2020).
  25. "Physicians work out treatment guidelines for coronavirus" (2020).
  26. "Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition)". China Law Translate (2020).
  27. Baron SA., et al. "Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?". International Journal of Antimicrobial Agents (2020): 105944.
  28. Cao B., et al. "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19". The New England Journal of Medicine (2020).
  29. Hoffmann M., et al. "The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells". Bio Rxiv (2020).
  30. Iwata-Yoshikawa N., et al. "TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection". Journal of Virology6 (2019).
  31. Liu R and Miller J. "China approves use of Roche drug in battle against coronavirus complications" (2020).
  32. "Effective Treatment of Severe COVID-19 Patients with Tocilizumab". ChinaXiv.org (2020).
  33. "3 patients get better on arthritis drug” (2020).
  34. "Coronavirus, via libera dell'Aifa al farmaco anti-artrite efficace su 3 pazienti e a un antivirale: test in 5 centri" [Coronavirus, Aifa gives go-ahead to effective anti-arthritis drug on 3 patients and an antiviral: test in 5 centers]. Il Messaggero (in Italian) (2020).
  35. "How doctors can potentially significantly reduce the number of deaths from Covid-19". Vox (2020).
  36. Ruan Q., et al. "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China". Intensive Care Medicine (2020).
  37. Mehta P., et al. "COVID-19: consider cytokine storm syndromes and immunosuppression". The Lancet (2020).
  38. "China turns Roche arthritis drug Actemra against COVID-19 in new treatment guidelines". Fierce Pharma (2020).
  39. Casadevall A and Pirofski LA. "The convalescent sera option for containing COVID-19". The Journal of Clinical Investigation (2020).
  40. Pearce K. "Antibodies from COVID-19 survivors could be used to treat patients, protect those at risk: Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic". The Hub at Johns Hopkins University (2020).
×

Citation

Citation: Vinayaka AM. “Things to be Know about the Coronavirus Illness (The Era of Covid-19)" Acta Scientific Nutritional Health 4.5 (2020): 03-09.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.034

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is October 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US